Gilead’s Letairis LEAP Frogs Encysive’s Thelin To PAH Market
Executive Summary
Gilead Sciences beat Encysive Pharmaceuticals in a race to bring a second endothelin receptor antagonist to market for the treatment of pulmonary arterial hypertension after FDA simultaneously granted approval to Gilead's Letairis and delayed approval of Encysive's Thelin June 15
You may also be interested in...
PAH’s Two Main Players Edging Toward Head-To-Head Competition
Although Pfizer Inc. and Gilead Sciences can be found at its margins, the pulmonary arterial hypertension space largely is a two-company competition. Currently, the two main players – United Therapeutics Corp. and Switzerland's Actelion Ltd. – have staked out a competitive advantage in a different portion of the space, but they are about to compete directly.
PAH’s Two Main Players Edging Toward Head-To-Head Competition
Although Pfizer Inc. and Gilead Sciences can be found at its margins, the pulmonary arterial hypertension space largely is a two-company competition. Currently, the two main players – United Therapeutics Corp. and Switzerland's Actelion Ltd. – have staked out a competitive advantage in a different portion of the space, but they are about to compete directly.
Gilead Surges On HIV In Q3, But Investors Pull Back With Myogen Purchase
The strength of Gilead's HIV portfolio, and particularly its newest addition Atripla, drew investor confidence in the third quarter, with the biopharmaceutical firm gaining 16.2% to reach a quarterly high close of 68.77 Sept. 29